144 - BioAge Labs, Inc. (0001709941) (Subject)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

424B5 - BioAge Labs, Inc. (0001709941) (Filer)

424B5 - BioAge Labs, Inc. (0001709941) (Filer)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

144 - BioAge Labs, Inc. (0001709941) (Subject)

8-K - BioAge Labs, Inc. (0001709941) (Filer)

144 - BioAge Labs, Inc. (0001709941) (Subject)

144 - BioAge Labs, Inc. (0001709941) (Subject)

144 - BioAge Labs, Inc. (0001709941) (Subject)

Piper Sandler initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $73.00

Morgan Stanley upgraded BioAge Labs from Underweight to Equal-Weight and set a new price target of $12.00

Citigroup upgraded BioAge Labs from Neutral to Buy and set a new price target of $10.00

William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

Citigroup downgraded BioAge Labs from Buy to Neutral and set a new price target of $7.00 from $45.00 previously

Citigroup initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $45.00

Jefferies initiated coverage of BioAge Labs with a rating of Buy and set a new price target of $42.00

Morgan Stanley initiated coverage of BioAge Labs with a rating of Overweight and set a new price target of $40.00

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4/A - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

4 - BioAge Labs, Inc. (0001709941) (Issuer)

EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435 shares of its common stock at a price to the public of $19.50 per share. The gross proceeds from this offering are expected to be approximately $115.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by BioAge. The offering is expected to close on or about January 23, 2026, subject to the satisfact

EMERYVILLE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75.0 million of shares of its common stock. In addition, BioAge intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock are being offered by BioAge. The proposed offering is subject to mar

BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence points to central role of the inflammasome in multiple retinal diseases where inflammation is a key feature, including diabetic macular edema (DME) BGE-102 has demonstrated favorable tolerability to date in ongoing Phase 1 trial, with robust reductions in key inflammatory biomarkers including hsCRP, IL-6, and IL-1β Proof-of-concept trial in DME is designed to demonstrate ocular target engagement, supporting future development across inflammation-driven retinal diseases DME tri

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels (<2 mg/L) BGE-102 demonstrated significant reductions in IL-6, a key driver of systemic inflammation and cardiovascular risk, and fibrinogen, an independent predictor of cardiovascular events BGE-102 was well tolerated with a favorable safety profile Patent issued covering additional composition of matter and novel NLRP3 binding site Full Phase 1 data, including additional MAD cohorts in obese participants with elevated hsCR

BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosing Strong target engagement: BGE-102 achieved 90-98% suppression of IL-1β, a cytokine directly downstream of NLRP3, at Day 14 High brain penetration: BGE-102 doses of 60 mg and higher exceeded target IC90 levels in cerebrospinal fluid (CSF) at Day 14 Company is expanding the Phase 1 trial to include MAD cohorts in participants with obesity and elevated hsCRP, with data anticipated in first half of 2026 EMERYVILLE, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic pro

EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Thursday, December 4 from 1:30 - 1:55 PM ET, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of

EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025. Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 - 7:55 AM ET (12:30 - 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here. Replays of the webcas

First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data expected by year-end Continued advancement of oral and parenteral APJ agonist programs targeting 2026 IND submissions EMERYVILLE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today provided business updates and reported its third quarter 2025 financial results. "The third quarter of 2025 marked an important milestone as we advanced BGE-102 into clinical development with the dosing of our fi

BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development.The initiation of the BGE-102 Phase 1 clinical study triggers a milestone payment to HitGen.CHENGDU, China, Sept. 15, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ((", BioAge", , NASDAQ:BIOA), a clinical-stage biotechnology company based in Emeryville, CA, USA, on the initiation of a Phase 1 clinical study of BGE-102, a novel, potent NLRP3 inhibitor developed fr

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ:BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences: Citi's 2025 Biopharma Back to School Conference (Boston, September 2–3, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Wednesday, September 3 at 3:15–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, regi

SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

SC 13D - BioAge Labs, Inc. (0001709941) (Subject)